(Q51774902)

12 April 2018

title

TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines. (English)

1 reference

12 April 2018

0 references

Dean Johnston

1

1 reference

12 April 2018

Bushra Zaidi

series ordinal

2

1 reference

12 April 2018

Jean-Claude Bystryn

series ordinal

3

1 reference

12 April 2018

publication date

1 December 2006

1 reference

12 April 2018

Cancer Immunology, Immunotherapy

published in

1 reference

12 April 2018

volume

56

1 reference

12 April 2018

issue

8

1 reference

12 April 2018

page(s)

1133-1141

1 reference

12 April 2018

https://scigraph.springernature.com/pub.10.1007/s00262-006-0262-3

exact match

0 references

cites work

Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS00262-006-0262-3

Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-006-0262-3

The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-006-0262-3

The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-alpha production in CD11c+CD11b+CD8- dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-006-0262-3

Introduction of soluble protein into the class I pathway of antigen processing and presentation

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1016/S0092-8674(88)91043-4

Identifiers

DOI

10.1007/S00262-006-0262-3

1 reference

12 April 2018

1 reference

12 April 2018